Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2003 1
2004 2
2006 2
2007 1
2012 1
2013 1
2015 2
2018 2
2020 3
2021 4
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
Aksoylu IS, Martin P, Robert F, Szkop KJ, Redmond NE, Bhattacharyya S, Wang J, Chen S, Beauchamp RL, Nobeli I, Pelletier J, Larsson O, Ramesh V. Aksoylu IS, et al. Among authors: beauchamp rl. Mol Autism. 2023 Oct 25;14(1):39. doi: 10.1186/s13229-023-00572-3. Mol Autism. 2023. PMID: 37880800 Free PMC article.
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.
Jordan JT, Orr CC, Thalheimer RD, Cambillo JV, Beauchamp RL, Shaikh G, Muzikansky A, Stemmer-Rachamimov A, Giovannini M, Kalamarides M, Barker FG 2nd, Ramesh V, Plotkin SR. Jordan JT, et al. Among authors: beauchamp rl. Neurooncol Adv. 2023 Apr 17;5(1):vdad041. doi: 10.1093/noajnl/vdad041. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37215956 Free PMC article.
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.
Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Haidar EA, Lule S, Mani G, Maalouf K, Stemmer-Rachamimov A, Jung DH, Welling DB, Giovannini M, Plotkin SR, Maguire CA, Ramesh V, Breakefield XO. Prabhakar S, et al. Among authors: beauchamp rl. Mol Ther Methods Clin Dev. 2022 Jun 22;26:169-180. doi: 10.1016/j.omtm.2022.06.012. eCollection 2022 Sep 8. Mol Ther Methods Clin Dev. 2022. PMID: 35846573 Free PMC article.
Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin.
Cheah PS, Prabhakar S, Yellen D, Beauchamp RL, Zhang X, Kasamatsu S, Bronson RT, Thiele EA, Kwiatkowski DJ, Stemmer-Rachamimov A, György B, Ling KH, Kaneki M, Tannous BA, Ramesh V, Maguire CA, Breakefield XO. Cheah PS, et al. Among authors: beauchamp rl. Sci Adv. 2021 Jan 8;7(2):eabb1703. doi: 10.1126/sciadv.abb1703. Print 2021 Jan. Sci Adv. 2021. PMID: 33523984 Free PMC article.
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW; Synodos for NF2 Consortium. Chang LS, et al. Among authors: beauchamp rl. PLoS One. 2021 Jul 15;16(7):e0252048. doi: 10.1371/journal.pone.0252048. eCollection 2021. PLoS One. 2021. PMID: 34264955 Free PMC article.
High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy.
Cheng C, Reis SA, Adams ET, Fass DM, Angus SP, Stuhlmiller TJ, Richardson J, Olafson H, Wang ET, Patnaik D, Beauchamp RL, Feldman DA, Silva MC, Sur M, Johnson GL, Ramesh V, Miller BL, Temple S, Kosik KS, Dickerson BC, Haggarty SJ. Cheng C, et al. Among authors: beauchamp rl. Sci Rep. 2021 Aug 23;11(1):17029. doi: 10.1038/s41598-021-96227-5. Sci Rep. 2021. PMID: 34426604 Free PMC article.
Translatome analysis of Tuberous Sclerosis Complex-1 patient-derived neural progenitor cells reveal rapamycin-dependent and independent alterations.
Aksoylu IS, Martin P, Robert F, Szkop KJ, Redmond NE, Chen S, Beauchamp RL, Nobeli I, Pelletier J, Larsson O, Ramesh V. Aksoylu IS, et al. Among authors: beauchamp rl. Res Sq [Preprint]. 2023 Mar 27:rs.3.rs-2702044. doi: 10.21203/rs.3.rs-2702044/v1. Res Sq. 2023. PMID: 37034588 Free PMC article. Updated. Preprint.
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium. Angus SP, et al. Among authors: beauchamp rl. Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046. Neuro Oncol. 2018. PMID: 29982664 Free PMC article.
25 results